Janney Montgomery Scott LLC Takes Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Janney Montgomery Scott LLC bought a new position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 72,729 shares of the biotechnology company's stock, valued at approximately $1,454,000.

A number of other large investors have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. lifted its position in shares of ADMA Biologics by 2.7% in the third quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company's stock worth $69,454,000 after purchasing an additional 92,281 shares in the last quarter. Seven Eight Capital LP bought a new stake in ADMA Biologics during the 2nd quarter worth about $1,992,000. Louisiana State Employees Retirement System acquired a new position in shares of ADMA Biologics during the 3rd quarter worth about $2,253,000. Point72 Asset Management L.P. acquired a new position in shares of ADMA Biologics during the 2nd quarter worth about $1,157,000. Finally, New York State Teachers Retirement System acquired a new stake in shares of ADMA Biologics in the third quarter valued at about $1,821,000. Institutional investors own 75.68% of the company's stock.

ADMA Biologics Stock Performance

NASDAQ:ADMA traded down $1.16 on Friday, hitting $19.04. The company's stock had a trading volume of 3,623,937 shares, compared to its average volume of 3,667,049. ADMA Biologics, Inc. has a one year low of $3.60 and a one year high of $23.64. The firm has a market capitalization of $4.44 billion, a P/E ratio of 68.00 and a beta of 0.64. The stock has a fifty day moving average of $18.49 and a two-hundred day moving average of $14.26. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The business had revenue of $119.84 million for the quarter, compared to analysts' expectations of $107.25 million. During the same quarter in the prior year, the business earned $0.01 EPS. Research analysts predict that ADMA Biologics, Inc. will post 0.52 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Young Kwon sold 60,000 shares of the firm's stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the transaction, the director now directly owns 241,441 shares of the company's stock, valued at approximately $4,408,712.66. This trade represents a 19.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the sale, the chief executive officer now owns 2,059,726 shares of the company's stock, valued at $36,436,552.94. This trade represents a 10.31 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 466,900 shares of company stock valued at $8,224,121. Company insiders own 3.70% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently commented on ADMA. HC Wainwright increased their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research report on Friday, November 8th. Cantor Fitzgerald reissued an "overweight" rating and issued a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. Finally, Raymond James boosted their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a report on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.